Pimavanserin free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317121

CAS#: 706779-91-1 (free base)

Description: Pimavanserin, also known as ACP-103, is an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors. Pimavanserin is a novel drug candidate for Parkinson's psychosis.Parkinson's disease psychosis (PDP) is a condition that may develop in up to 60 % of Parkinson's patients, and is a major reason for nursing home placement for those affected.

Chemical Structure

Pimavanserin free base
CAS# 706779-91-1 (free base)

Theoretical Analysis

MedKoo Cat#: 317121
Name: Pimavanserin free base
CAS#: 706779-91-1 (free base)
Chemical Formula: C25H34FN3O2
Exact Mass: 427.26351
Molecular Weight: 427.56
Elemental Analysis: C, 70.23; H, 8.02; F, 4.44; N, 9.83; O, 7.48

Price and Availability

Size Price Availability Quantity
100.0mg USD 250.0 2 Weeks
200.0mg USD 450.0 2 Weeks
500.0mg USD 750.0 2 Weeks
1.0g USD 1050.0 2 Weeks
2.0g USD 1850.0 2 Weeks
5.0g USD 3050.0 2 Weeks
10.0g USD 4650.0 2 Weeks
Bulk inquiry

Related CAS #: 706779-91-1 (free base)   706782-28-7 (tartrate)    

Synonym: ACP-103; ACP 103; ACP103; Pimavanserin; trade name: Nuplazid.

IUPAC/Chemical Name: N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide


InChi Code: InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 427.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548120/ PubMed PMID: 31643450.

2: Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review. Cureus. 2019 Jul 28;11(7):e5257. doi: 10.7759/cureus.5257. Review. PubMed PMID: 31572642; PubMed Central PMCID: PMC6760879.

3: Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Review. PubMed PMID: 31159608.

4: Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. CNS Spectr. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359. Review. PubMed PMID: 30588905.

5: Patel N, LeWitt P, Neikrug AB, Kesslak P, Coate B, Ancoli-Israel S. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Clin Neuropharmacol. 2018 Nov/Dec;41(6):210-215. doi: 10.1097/WNF.0000000000000307. Review. PubMed PMID: 30303817.

6: Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, Norton J, Stankovic S. Pimavanserin: Potential Treatment For Dementia-Related Psychosis. J Prev Alzheimers Dis. 2018;5(4):253-258. doi: 10.14283/jpad.2018.29. Review. PubMed PMID: 30298184; PubMed Central PMCID: PMC6413822.

7: Kitten AK, Hallowell SA, Saklad SR, Evoy KE. Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. Innov Clin Neurosci. 2018 Feb 1;15(1-2):16-22. Review. PubMed PMID: 29497575; PubMed Central PMCID: PMC5819716.

8: Hawkins T, Berman BD. Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract. 2017 Apr;7(2):157-162. doi: 10.1212/CPJ.0000000000000342. Review. Erratum in: Neurol Clin Pract. 2017 Aug;7(4):282. PubMed PMID: 29185542; PubMed Central PMCID: PMC5669409.

9: Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Expert Opin Drug Discov. 2018 Jan;13(1):103-110. doi: 10.1080/17460441.2018.1394838. Epub 2017 Oct 31. Review. PubMed PMID: 29047301.

10: Duits JH, Ongering MS, Martens HJM, Schulte PFJ. [Pimavanserin: a new treatment for the Parkinson's disease psychosis]. Tijdschr Psychiatr. 2017;59(9):528-536. Review. Dutch. PubMed PMID: 28880354.

11: Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17. Review. PubMed PMID: 28817967.

12: Hermanowicz N, Alva G, Pagan F, Espay AJ, Patel A, Madrid KC, Kremens D, Kenney J, Arquette S, Tereso G, Lopes M, Farnum C. The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis. J Manag Care Spec Pharm. 2017 Jun;23(6-b Suppl):S2-S8. doi: 10.18553/jmcp.2017.23.6-b.s2. Review. PubMed PMID: 28636480.

13: Mathis MV, Muoio BM, Andreason P, Avila AM, Farchione T, Atrakchi A, Temple RJ. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. J Clin Psychiatry. 2017 Jun;78(6):e668-e673. doi: 10.4088/JCP.16r11119. Review. PubMed PMID: 28493654.

14: Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Ann Pharmacother. 2017 Jun;51(6):479-487. doi: 10.1177/1060028017693029. Epub 2017 Feb 1. Review. PubMed PMID: 28375643.

15: Combs BL, Cox AG. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat. 2017 Mar 8;13:737-744. doi: 10.2147/NDT.S108948. eCollection 2017. Review. PubMed PMID: 28331324; PubMed Central PMCID: PMC5352252.

16: Sarva H, Henchcliffe C. Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Ther Adv Neurol Disord. 2016 Nov;9(6):462-473. Epub 2016 Oct 3. Review. PubMed PMID: 27800022; PubMed Central PMCID: PMC5066530.

17: Chendo I, Ferreira JJ. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother. 2016 Oct;17(15):2115-24. doi: 10.1080/14656566.2016.1234609. Epub 2016 Sep 15. Review. PubMed PMID: 27609312.

18: Markham A. Pimavanserin: First Global Approval. Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9. Review. PubMed PMID: 27262680.

19: Hunter NS, Anderson KC, Cox A. Pimavanserin. Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001. Review. PubMed PMID: 26744739.

20: Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review. PubMed PMID: 24682754; PubMed Central PMCID: PMC4172996.

Additional Information

Related CAS#
706779-91-1 ( Pimavanserin )
706782-28-7 (Pimavanserin tartrate)